Mechanistic and translational studies further support TREM2 as a therapeutically tractable macrophage checkpoint; effector-enhanced anti-TREM2 antibodies and modalities delivering TREM2-directed binders into the tumor bed improve responses to PD-1 therapy, including in CRC models (75, 76). This evidence concerns the gene TREM2 and colorectal carcinoma.